OXFORD NANOPORE TECHNOLOGIES PLC

Report Publication Announcement • Nov 7, 2025

National Storage Mechanism | Additional information

RNS Number : 6582G

Oxford Nanopore Technologies plc

07 November 2025

Oxford Nanopore Technologies plc

("Oxford Nanopore" or the "Company")

Oxford Nanopore postpones virtual investor event; reaffirms guidance

07 November 2025

Oxford Nanopore Technologies plc (LSE: ONT), the company delivering a new generation of molecular sensing technology based on nanopores, today announces that, with the CEO succession process actively underway, the Company is postponing the previously planned 14 November virtual investor seminar pending appointment of the new CEO.

The Company expects full-year 2025 constant currency revenue growth to be at the top end of its previously stated guidance range of 20-23%, with all other financial metrics tracking in line with expectations.

​

-ENDS-

For further information, please contact:

Oxford Nanopore Technologies plc

Investors:         [email protected]

Media:              [email protected]

Teneo (communications adviser to the Company)

Tom Murray, Lisa Jarrett-Kerr

+44 (0) 20 7353 4200

[email protected]

About Oxford Nanopore Technologies plc:

Oxford Nanopore Technologies' goal is to bring the widest benefits to society through enabling the analysis of anything, by anyone, anywhere. The Group has developed a new generation of nanopore-based sensing technology that is currently used for real-time, high-performance, accessible, and scalable analysis of DNA and RNA. The technology is used in more than 125 countries, to understand the biology of humans, plants, animals, bacteria, viruses and environments as well as to understand diseases such as cancer.  Oxford Nanopore's technology also has the potential to provide broad, high impact, rapid insights in a number of areas including healthcare, food and agriculture.

For more information please visit: www.nanoporetech.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCUPGPAGUPAUMM